Arca
Skip to content
Tools
Tools

REN: Renin

Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney. .

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on REN, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved1

  • Aliskiren

Phase 31

  • Sitokiren

Phase 21

  • Imarikiren

Phase 10

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Renin inhibitor.
    AliskirenBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitor1
    SitokirenPhase 3Shanghai Pharmaceuticals Holding Co., LtdSmall moleculeInhibitor0
    ImarikirenPhase 2—Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 1 in all, from ClinicalTrials.gov.
    TrialDrugPhaseStatusLead sponsorFirst posted
    Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyAliskirenPhase 2RecruitingRegion SkaneDec 3, 2019

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Familial juvenile hyperuricemic nephropathy type 20.76
    • Renal tubular dysgenesis0.74
    • Renal tubular dysgenesis of genetic origin0.73
    • Hypertensive disorder0.67
    • Stroke disorder0.47
    • Hereditary disease0.42
    • Cardiovascular disorder0.39
    • Congenital anomaly of kidney and urinary tract0.37

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL286, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P00797, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.